From the Authors :
Dean and colleagues are confirming our previous observation on the risk of paradoxical worsening after introduction of HAART in patients with Pneumocystis carinii pneumonia (PCP) (1) . Since the publication of our paper, we observed three new cases. The 18% prevalence of paradoxical worsening of PCP reported by Dean and colleagues is higher than that we have previously shown. In our experience, paradoxical worsening of PCP represents 4.6% of the patients referred for PCP to our instititution, and 7% of those receiving steroids because of acute respiratory failure. This discrepancy probably reflects variation of the incidence of severe PCP between institutions, and the diversity of schedules of adjunctive steroid therapy and of HAART introduction used in severe PCP (2, 3) .
All the patients reported with paradoxical worsening of PCP had a very similar presentation. All had severe PCP (Pa O 2 Ͻ 70 mm Hg) requiring adjunctive steroids. Moreover, HAART was introduced early after PCP diagnosis (1 to 16 days) and steroid therapy was stopped too early ( Ͻ 15 days). Lastly, this phenomenon occurs in severely immunocompromised patients in whom a dramatic decrease of plasma viral load was observed after HAART introduction. The peripheral blood CD4 cell counts did not increase in parallel, suggesting CD4 cell pulmonary sequestration as shown in lung tissue specimen (1). However, it is also important to emphasize that the diagnosis of paradoxical PCP worsening implies that cotrimoxazole-resistant PCP, pulmonary superinfection, and drug-induced pulmonary toxicity have been previously ruled out.
Finally, the fact that patients with paradoxical PCP worsening improved after HAART discontinuation or steroid introduction suggests either the need for an overlap period between HAART introduction and steroid cessation in the case of early HAART introduction, or to delay HAART introduction until after the end of PCP steroid adjunctive therapy. Whatever the measure adopted to prevent paradoxical PCP worsening after HAART introduction, steroid adjunctive therapy might probably not be shorter than 3 weeks, as recommended by consensus statement (4 Corradi and colleagues report that the concentration of S-nitrosothiols (RSNO), nitrite, and exhaled nitric oxide (eNO) are increased in some inflammatory airway diseases. The chemistry of reactive nitrogen species (RNS) in biological systems is complex (2) and it is still unclear whether point estimates of concentration of RNS in blood and urine provide information on endogenous NO metabolism (3) . Although collection of exhaled breath condensate (EBC) and eNO measurements may offer attractive alternative methods for measuring RNS, great care in sample handling and interpretation of results is mandatory.
EBC was collected using a glass condensing device, by cooling of the exhalate during tidal breathing for 15 minutes while wearing a nose clip. Contamination by trace transition metals, leaching from any glass containers, and exposure to light may have accelerated RSNO decomposition. Total RSNO content in EBC was measured by spectrophotometry, using a method adapted from Saville and Griess that involves cleavage of the NO group with mercuric chloride followed by quantitative detection of nitrite in the diazotation assay (the Griess assay). Artifactual loss of nitrite due to its disproportionation to NO or nitrosation of the remaining thiol-containing compounds in the EBC during the necessary sample acidification step in the Griess assay, would also be a possibility. Exhaled breath measurements in inflammatory disorders are prone to additional confounding factors. For example, we have recently confirmed that nitrite releases free NO even at physiological pH (4) . Moreover, recent advances by Hunt and Gaston (5) suggest that endogenous airway acidification is a pathological feature of asthma. This would accelerate decomposition of nitrite to NO producing eNO (4, 5) .
The cellular origin of exhaled RNS varies according to the disease. The elevated concentrations of eNO in asthma could be from epithelial NOS II (inducible NOS) or of neural origin (6) . Identification of the isoform of NOS responsible for RNS production in inflammatory disorders will have to await the introduction of selective inhibitors of the different isoforms of the enzyme. Monitoring RNS in biological milieu is a challenging endeavour, and selective methods to measure endogenous NO production in vivo will certainly help unravel the complex interactions between nitrogen oxides and their derivatives. 
We thank Dr. Demoncheaux and coworkers for their insightful comments on our article raising concerns about the measurement of reactive nitrogen species in exhaled breath condensate (1). Demoncheaux and colleagues suggest that exhaled breath condensate samples may be contaminated by trace transition metals from any glass containers or tubing, and that exposure to light may accelerate the decomposition of S-nitrosothiols. There is currently no evidence that either of these factors have any influence on the concentrations of S-nitrosothiols in exhaled breath condensate, but systematic studies are needed. We have shown that the concentrations of S-nitrosothiols are identical to those reported in our manuscript when using a condenser system that does not contain any glass component and is protected from light, suggesting that these factors are unlikely to have any significant effect on measurements. Furthermore, we looked at concentrations of S-nitrosothiols in different groups of subjects, and are more interested in the differences between these groups than the absolute concentrations in the samples.
Demoncheaux and colleagues are concerned that airway acidification may reduce the concentrations of S-nitrosothiols in patients with asthma. In fact, the pH of exhaled breath condensate is no different than normal in stable asthma and is lower only during acute exacerbations (2, 3) .
We agree that selective NOS inhibitors will help us to identify the isoforms of NOS responsible for the production of reactive nitrogen species in inflammatory diseases of the lungs. We have previously demonstrated that inhaled aminoguanidine, which has some selectivity in inhibiting inducible NOS, causes a greater reduction in exhaled NO in patients with asthma compared with normal control subjects (4). Our recent unpublished observations have demonstrated that a more potent and specific iNOS inhibitor was capable of reducing exhaled NO by over 90% in patients with asthma, confirming that iNOS accounts for the majority of exhaled NO in asthma.
Monitoring of markers in exhaled breath condensate in patients with pulmonary disease has enormous potential as a noninvasive means of monitoring airway inflammation and oxidative stress (5), and represents a clear way forward rather than a difficult journey. P ETER J. B ARNES S ERGEI A. K HARITONOV National Heart and Lung Institute, Imperial College London, United Kingdom
RAPID TRANSLOCATION OF NANOPARTICLES FROM THE LUNG TO THE BLOODSTREAM?
To the Editor :
In their brief communication, Nemmar and colleagues (1) report rapid clearance of instilled albumin nanoparticles from the lungs to the bloodstream of hamsters (25-30% in 5 minutes), suggesting an explanation for observed cardiovascular effects of urban, airborne particulate matter reported in epidemiological studies (2) . Although this hypothesis is attractive, the results of this particular study (1) are in conflict with decades of studies on respiratory clearance of aerosolized solutes (3) (4) (5) (6) . In particular, Peterson and colleagues (3) found that aerosolized Tc99m-aggregated albumin (mol wt ϭ 383,000 daltons; approx mol size ϭ 20 nm) similar to the tracer used by Nemmar and colleagues (1), delivered to the lungs of sheep cleared exponentially at a rate of 0.04% per minute over an 80-minute period (less than 5% lung clearance during that time). Even the rate constant for the smallest tracer (DTPA) used in their study (3) was only 0.4% per minute with less than 10% clearance in 30 minutes. These data are inconsistent with the observations of Nemmar and colleagues (1), i.e., a rapid rate of 5-6% per minute.
Huchon and colleagues (4) also studied the clearance of a variety of aerosolized, radioactive solutes from the lungs of dogs. They found that solute clearance was inversely related to molecular weight, with negligible clearance of the largest molecular weight solute, labeled transferrin (mol wt ϭ 76,000 daltons), over a 30-minute period of observation. At the other extreme, free pertechnetate (TcO 4 Ϫ ) (mol wt ϭ 163 daltons) had a clearance rate of 6% per minute. Clearance rates in humans (5, 6) for aerosolized solutes that are smaller in molecular size than that employed by Nemmar and colleagues (1) are also considerably slower than that seen during the first 5 minutes of observation in their study.
The above cited studies are only a few of many that are incompatible with the study by Nemmar and colleagues. The reasons for these differences are not clear, but one clear difference in protocol is that particles were instilled in their study rather than inhaled. Nevertheless, it is important that the authors fully address the discrepancies between their results and previous findings and possible reasons for those differences. Careful study of inhaled particle dosimetry is needed to lead toxicologists towards a better understanding of the biological effects of exposure to ambient particulate matter (2 
